Mumbai, June 30 -- Shares of JB Chemicals & Pharmceuticals declined 6.63% to Rs 1,680.05 on the BSE.

The acquisition would provide access to a fast growing India franchise, with leading brands in the chronic segment, and entry into untapped therapeutic areas like ophthalmology. It strengthens market share in the IPM for Torrent and offers operational synergies across multiple business functions.

The deal also supports platform diversification through entry into the CDMO segment with long-term potential. Additionally, it facilitates consolidation in key international markets and greater ability to scale up.

The transaction will be executed in two phases. In first phase, the company will acquire 7,44,81,519 equity shares, representing a ...